LEO Pharma Announces Changes to Executive Leadership
29.1.2025 14:00:00 CET | LEO Pharma | Pressemeddelelse
null
Ballerup, 29 January 2025 – Today, LEO Pharma announces the appointment of a new Executive Vice President, North America. Robert Spurr will join the Global Leadership Team and serve as CEO and President, LEO Pharma Inc. United States. Robert succeeds Brian Hilberdink, who will be leaving LEO Pharma to pursue an external opportunity in a large pharmaceutical company.
Robert joined LEO Pharma in 2023 as Vice President of Market Access, Patient Services, Sales, and Health Economics and Outcomes Research (HEOR) and a member of the North America Leadership Team. Prior to LEO Pharma, he previously held numerous senior leadership positions at Novartis, Johnson and Johnson, and Repligen. Robert also served as President of Bausch Healthcare Companies Inc.
“I am thrilled to step into the role of EVP of Region North America and CEO & President of LEO Pharma Inc. US,” said Robert Spurr “As LEO Pharma undergoes significant transformation with a clear strategy for the future, I am eager to leverage my experience to drive our continued success. With a strong growth trajectory and a dedicated team, I am confident we can deliver great results.”
Robert Spurr will officially step into the EVP role on January 29, 2025. Brian Hilberdink’s last day at LEO Pharma will be on February 11, 2025.
“During my tenure at LEO Pharma, I have witnessed the incredible drive and passion across Region North America. I’m proud to have had the opportunity to lead and help propel the Region into a significant growth trajectory,” said Brian Hilberdink, former EVP of Region North America and CEO & President of LEO Pharma Inc. US. “It has not been an easy decision to leave LEO Pharma, and I have every confidence in the future success of the organization.”
“I would like to thank Brian for his key contribution in accelerating LEO Pharma’s growth trajectory in North America and for building a strong team,” said LEO Pharma CEO, Christophe Bourdon. “Robert’s track record and leadership qualities make him ideally suited to his new role. Over the last 18 months I have been truly impressed by his key contributions to the US affiliate. I would like to congratulate him on his appointment and welcome him as a member of LEO Pharma’s Global Leadership Team. His contributions will be instrumental in further strengthening our growth trajectory in North America.”
Kontakter
Jeppe Ilkjær
LEO Pharma, Global Communications
Tel: +45 30 50 20 14
Email: JEILK@leo-pharma.com
About LEO Pharma
LEO Pharma is a global company dedicated to advancing the standard of care through innovation for the benefit of people with skin conditions. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. LEO Pharma offers a broad portfolio of treatments, serving 100 million patients annually. Headquartered in Denmark, LEO Pharma has a global team of 4,000 people. In 2023, the company generated net sales of DKK 11.4 billion.
Følg pressemeddelelser fra LEO Pharma
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra LEO Pharma
LEO Pharma lancerer LOQTORZI® (toripalimab) på hjemmemarkedet i Danmark7.5.2026 09:00:00 CEST | Pressemeddelelse
LOQTORZI® (toripalimab) lanceres i kombination med standardkemoterapi i Danmark som en ny førstelinjebehandling til voksne patienter med recidiverende eller metastatisk nasopharyngeal cancer, som ikke kan behandles med kirurgi eller strålebehandling (R/M NPC).¹ LOQTORZI® har vist en dokumenteret overlevelsesgevinst og kan udgøre en potentiel ny standardbehandling for patienter med fremskreden R/M NPC.² Langtidsdata fra det kliniske JUPITER-02-studie viser, at LOQTORZI® i kombination med kemoterapi giver vedvarende og signifikante forbedringer i både samlet overlevelse (OS) og progressionsfri overlevelse (PFS) sammenlignet med kemoterapi alene¹, hvilket etablerer en ny behandlingsmulighed for patienter med R/M NPC Lanceringen styrker LEO Pharmas Critical Care-portefølje på hjemmemarkedet i Danmark og demonstrerer virksomhedens engagement i at bringe nye behandlinger til patienter – via en etableret specialiseret kommerciel platform til hospitaler.
LEO Pharma delivers 9% revenue growth at CER in Q1 2026 and strengthens innovation pipeline5.5.2026 09:00:00 CEST | Pressemeddelelse
Ballerup, Denmark, 5 May, 2026 – In Q1 2026, LEO Pharma delivered robust revenue growth, driven by the dermatology portfolio, and improved profitability while significantly increasing commercial investments to support the global roll-out of Anzupgo® and the addition of Spevigo® to the portfolio. LEO Pharma also made significant strategic progress and advanced innovation through the acquisition of Replay’s next-generation gene therapy platform targeting rare genetic skin diseases, the approval of Enstilar® in China and the continued late-stage development activities for Anzupgo®, including FDA acceptance for review in adolescents with chronic hand eczema. Financial highlights LEO Pharma’s revenue increased by 4% to DKK 3,521 million, and by 9% at constant exchange rates (CER). The revenue growth was led by North America (30% at CER) and Rest of World (13% at CER), whereas sales in Europe declined by 1% at CER. Revenue from the dermatology portfolio grew by 11% (CER), driven by the strat
LEO Pharma bolsters rare skin disease focus through acquisition of Replay gene therapy platform30.4.2026 15:00:00 CEST | Pressemeddelelse
Acquisition adds high-payload herpes simplex virus (HSV) gene therapy targeting genetic skin diseases to LEO Pharma’s pipeline and further expands the company’s presence in rare dermatology Combines LEO Pharma’s six decades of dermatology expertise with Replay’s next-generation gene therapy platform to advance innovation for patients with rare skin diseases The lead program targets dystrophic epidermolysis bullosa (DEB), a devastating genetic skin disease with significant unmet medical need.
LEO Pharma expands its psoriasis portfolio in China with NMPA approval of Enstilar®17.4.2026 09:00:00 CEST | Pressemeddelelse
NMPA approval of Enstilar® in China marks a significant milestone for LEO Pharma, expanding access to a new treatment option for the estimated 6.5 million adults living with plaque psoriasis in the world’s largest market measured by patient numbers.1 China represents a strategically important pillar in LEO Pharma’s long-term growth, and the approval strengthens the company’s position in medical dermatology by expanding its psoriasis portfolio in an exciting market for innovative treatments. Enstilar builds on LEO Pharma’s established leadership in topical psoriasis treatments, offering a clinically proven, foam-based formulation that has been widely adopted in more than 50 markets worldwide and is supported by robust phase 3 clinical data.2,3
LEO Pharma announces FDA Acceptance of supplemental NDA for ANZUPGO® (delgocitinib) cream for the treatment of Chronic Hand Eczema in children aged 12-1715.4.2026 14:00:00 CEST | Pressemeddelelse
The application is supported by positive data from the pivotal Phase 3 DELTA TEEN trial in the primary and key secondary endpoints.1 If approved, ANZUPGO will be the first treatment option specifically indicated for pediatric patients aged 12–17 living with moderate to severe chronic hand eczema (CHE).
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum